EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL

Deyan Y Yosifov iD, Sandra Robrecht, Adam Giza, Palash C Maity, Armin Riecke, Christof Schneider, Billy M C Jebaraj, Rashmi P Dheenadayalan, Hassan Jumaa, Marc Young, Manish Kumar, Lothar Müller und 13 weitere

HemaSphere · 2026-06 · 10 (6)

DOI: 10.1002/hem3.70385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 15.06.2026. Verfasst von Deyan Y Yosifov und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson, Fritz Thyssen Stiftung, Deutsche Forschungsgemeinschaft.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IGLV3‐21 R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors. Here, we analyzed samples from the phase 3 CLL12 study that compared ibrutinib vs. placebo in untreated early‐stage CLL patients with intermediate to very high risk of disease progression, while patients with low risk of disease progression were allocated to watch‐and‐wait (w&w). Four detection methods (targeted next‐generation sequencing, Sanger sequencing, multiplex IGLV3‐21 R110 ‐specific PCR, and flow cytometry) were compared, yielding highly consistent results. Overall, 34/515 (6.6%) patients had productive IGLV3‐21 rearrangements: 5/152 (3.3%) in w&w, 15/181 (8.3%) in placebo, and 14/182 (7.7%) in the ibrutinib group. Of these, 25 were IGLV3‐21 R110 ‐positive (3/5, 12/15, and 10/14). IGLV3‐21 R110 was associated with shorter event‐free survival (EFS) across all arms: w&w (hazard ratio [HR] 17.03, 95% confidence interval [CI 95%]: 4.99–58.13, P < 0.001), placebo (HR 2.31, CI 95%: 1.16–4.6, P = 0.017), and ibrutinib (HR 2.99, CI 95%: 1.17–7.65, P = 0.023). Multivariable analysis identified IGLV3‐21 R110 as an independent prognostic factor for shorter EFS (HR 3.18, CI 95%: 1.73–5.83, P < 0.001). Notably, IGLV3‐21 R110 was associated with reduced clinical effectiveness of ibrutinib. Ca 2+ ‐flux and cell viability assays using patient‐derived BCRs expressed in murine B‐cells confirmed reduced ibrutinib efficacy in IGLV3‐21 R110 cases, especially regarding inhibition of antigen‐stimulated signaling. In summary, IGLV3‐21 R110 is an independent prognostic factor for shorter EFS in early‐stage CLL and reduces ibrutinib effectiveness clinically and in vitro.

Autor:innen und Institutionen

  • Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.
  • German Cancer Research Center (DKFZ) Heidelberg Germany.
  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.
  • German CLL Study Group University of Cologne Cologne Germany.
  • Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany.
  • Internal Medicine, Division of Hematology German Military Hospital Ulm Ulm Germany.

ORCID-Profile: Deyan Y Yosifov, Barbara Eichhorst

Förderung

  • Johnson and Johnson
  • Fritz Thyssen Stiftung
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Yosifov, D. Y., Robrecht, S., Giza, A., Maity, P. C., Riecke, A., Schneider, C., Jebaraj, B. M. C., Dheenadayalan, R. P., Jumaa, H., Young, M., Kumar, M., Müller, L., Vehling-Kaiser, U., Eckart, M., Freier, W., Schöttker, B., Gaska, T., Reiser, M., Fink, A. M., …, & Stilgenbauer, S. (2026). IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70385

Vancouver

Yosifov DY, Robrecht S, Giza A, Maity PC, Riecke A, Schneider C, et al. IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL. HemaSphere. 2026;10(6). doi:10.1002/hem3.70385

BibTeX
@article{Yosifov2026,
  author = {Yosifov, Deyan Y and Robrecht, Sandra and Giza, Adam and Maity, Palash C and Riecke, Armin and Schneider, Christof and Jebaraj, Billy M C and Dheenadayalan, Rashmi P and Jumaa, Hassan and Young, Marc and Kumar, Manish and Müller, Lothar and Vehling-Kaiser, Ursula and Eckart, Michael and Freier, Werner and Schöttker, Björn and Gaska, Tobias and Reiser, Marcel and Fink, Anna-Maria and Fischer, Kirsten and Eichhorst, Barbara and Hallek, Michael and Langerbeins, Petra and Tausch, Eugen and Stilgenbauer, Stephan},
  title = {IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1002/hem3.70385}
}
Kostenlos starten →